Highlights

  • 4DMedical has secured regulatory approvals for CT:VQ across the US, Europe and Australia.
  • US Medicare reimbursement creates a defined payment pathway for eligible CT:VQ scans.
  • Investors remain focused on whether regulatory milestones translate into higher commercial adoption.
  • Upcoming quarterly and annual updates are expected to provide further insight into commercial progress.

The Melbourne lung-imaging company has spent the past year collecting regulatory clearances and reimbursement approvals across three continents. Yet its recent share-price volatility highlights that for 4DMedical, the real test is turning approvals into paying scan volumes.

Why investors are watching

Few ASX healthcare names divide opinion as sharply as 4DMedical. The company has built a differentiated technology—software that extracts quantitative, functional information about how a patient's lungs actually work from standard CT and X-ray equipment—and it has assembled the regulatory and reimbursement framework to commercialise the technology across the United States, Europe and Australia. Despite these milestones, commercial revenue remains relatively modest, highlighting the gap between technological progress and widespread adoption.

That tension came to a head during July 2026, when investor sentiment weakened after the market reassessed a piece of United States legislation the company had welcomed only days earlier.

The latest catalyst

On 15 July 2026, a bipartisan bill known as the AIR CARE for Veterans Act (H.R. 9666) was introduced in the US House of Representatives. It directs the Department of Veterans Affairs to establish a pilot program using FDA-cleared functional lung-imaging technology—precisely the category 4DMedical occupies. Management described it as an important step given the large veteran population affected by occupational and battlefield lung injury.

The market's second read was cooler. The bill is an authorisation rather than guaranteed funding: it contemplates roughly US$25 million over five years from 2027, names no vendor, and must still pass Congress. The episode illustrates how 4DMedical's news flow can generate varying market reactions while investors wait for commercial outcomes.

Attention has also been focused on the June 2026 quarterly cash-flow report (Appendix 4C). As at the time of writing, that filing was due but its specific receipts and cash-burn figures had not yet been publicly confirmed, so they are not reported here.

The business and the numbers

4DMedical sells its analysis as software-as-a-service: clinicians upload scans, the company processes them in the cloud, and quantitative lung-function reports are returned, billed per scan or through subscription arrangements. Its lead growth product, CT:VQ, is a non-contrast CT-based ventilation-perfusion tool that received US FDA clearance on 4 September 2025, a European CE Mark on 30 March 2026 and Australian TGA approval on 28 June 2026—a full regulatory sweep across its three target markets within a year.

The company also secured US Medicare reimbursement for CT:VQ under the calendar-2026 outpatient framework, reported at roughly US$650 per scan in addition to the standard chest CT fee. This provides hospitals with a defined reimbursement pathway. The balance sheet was also strengthened following a placement of more than US$100 million completed around 20 January 2026, lifting pro-forma cash to about A$206 million. In June 2026, the company agreed to acquire Vienna-based imaging software developer contextflow for about US$18.6 million to establish a European platform.

The unresolved issue is commercial conversion. Half-year revenue to 31 December 2025 was A$2.85 million, essentially flat year on year, while the reported net loss of A$154.1 million was largely driven by a A$137.8 million non-cash fair-value adjustment on a financing instrument linked to Pro Medicus. Excluding that adjustment, the adjusted loss was about A$16.2 million, with operating cash outflow of roughly A$12.7 million for the half.

Industry context

The company operates in the niche where AI-enabled imaging meets respiratory diagnostics, targeting COPD, asthma, interstitial lung disease, lung cancer screening and occupational lung injury. Its technology provides quantitative functional data using imaging equipment already installed in hospitals, without relying on radioactive tracers commonly associated with traditional nuclear medicine scans. The key commercial milestones for medical imaging software remain regulatory clearance, reimbursement and clinical adoption. The first two have largely been achieved, while broader clinical uptake remains the next challenge.

The bull case

Supporters argue the major regulatory hurdles have largely been cleared. CT:VQ now holds approvals across three major markets, Medicare reimbursement has established a payment pathway, the company has funding to support commercial expansion, and the contextflow acquisition provides a foundation for growth in Europe. Broader adoption across existing CT infrastructure could expand recurring software revenue over time, while the proposed veterans legislation may create additional institutional opportunities if enacted.

The bear case and risks

Others point to the pace of commercial execution. Revenue remained relatively flat despite multiple regulatory achievements, suggesting that reimbursement approval alone does not immediately translate into commercial revenue. The company continues to report losses and operating cash outflows, while its capital structure remains affected by the Pro Medicus financing instrument. Investors are likely to remain focused on whether future contract wins and scan volumes justify expectations.

What to watch next

The nearest catalyst is the June 2026 Appendix 4C, which is expected to provide further insight into CT:VQ commercial activity under the Medicare reimbursement pathway, followed by the company's full-year results expected around August 2026. Investors will also monitor hospital contract wins, scan volumes in the United States, completion of the contextflow acquisition and European rollout, expansion in Australia following TGA approval, and the progress of H.R. 9666 through Congress.

4DMedical has spent the past year demonstrating that regulators and healthcare payers accept its technology. The next phase will depend on broader clinical adoption and whether increasing utilisation is reflected in future financial performance.